The Global Recombinant Chemicals Market is valued at approximately USD 2.9 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 7.8% over the forecast period 2024-2032.

The bioengineered protein drugs market is experiencing a paradigm shift, with pharmaceutical and biotech companies leveraging advanced biopharmaceuti ...

Therapeutic proteins are increasingly becoming an indispensable part of healthcare, with their applications found in treating both infectious diseases, and non-communicable diseases such as ...

iAccess Alpha hosts virtual investor conferences featuring companies recommended by investors. These two-day events include webcast presentations on Day 1, followed by one-on-one meetings between ...

As global markets grapple with inflation fluctuations and trade policy uncertainties, Asian tech stocks have emerged as a focal point for investors seeking growth opportunities amid broader market ...

Gilead Sciences announced a significant milestone: the U.S. FDA accepted their New Drug Applications (NDAs) for lenacapavir ...

AstraZeneca has signed two deals worth $1.35 billion with Alteogen to develop subcutaneous versions of the British pharma’s ...

SineuGene Therapeutics receives US FDA’s investigational new drug application clearance for SNUG01 to treat amyotrophic lateral sclerosis: Beijing Thursday, March 27, 2025, 15:0 ...

Good evening and welcome to Dyadic International's Year-End 2024 Conference Call. Currently, all participants are in a listen-only mode. Following management's prepared remarks, there will be a brief ...

Penmenvy (meningococcal Groups A, B, C, W, and Y vaccine) Meningococcal vaccine For active immunization to prevent invasive disease caused by Neisseria meningitidis serogroups A, B, C, W, and Y in ...